Quarterly Result12 Aug 2025, 05:44 pm
Jenburkt Pharmaceuticals Ltd. Announces Q1 2025 Financial Results with 18.2% YoY Revenue Growth
AI Summary
Jenburkt Pharmaceuticals Ltd. has announced its standalone unaudited financial results for the quarter ended on 30th June, 2025. The company's revenue from operations has grown by 18.2% YoY to Rs. 4,104.69 Lacs. The total expenses for the quarter stood at Rs. 3,394.14 Lacs, with profit before tax at Rs. 1,018.20 Lacs. The company's total comprehensive income for the quarter is Rs. 777.66 Lacs. The Board of Directors has approved these results in their meeting held on 12th August, 2025.
Key Highlights
- Revenue from operations for Q1 2025 stands at Rs. 4,104.69 Lacs, a YoY growth of 18.2%.
- Total expenses for the quarter are Rs. 3,394.14 Lacs.
- Profit before tax for the quarter is Rs. 1,018.20 Lacs.
- Total comprehensive income for the quarter is Rs. 777.66 Lacs.
- The Audit Committee and the Board of Directors have reviewed and approved the standalone unaudited financial results.